The National Agency for Food and Drug Administration and Control (NAFDAC) has announced a nationwide mop-up of pharmaceutical products manufactured by Europharm Laboratories, Jos, after uncovering serious regulatory and quality violations.
In a statement posted on its official X handle on Friday, the agency said it had commenced enforcement action against Europharm Laboratories and its affiliate, Eurolink Nigeria Ltd., located at Plot PL 7354, Anglo Jos, New Industrial Area.
The agency said their action followed credible intelligence and routine regulatory surveillance.
Investigations revealed that the company had been producing, selling, and distributing several pharmaceutical and other regulated products without the required Marketing Authorisation (MA).
Multiple products were found at the facility, many of which were being manufactured or circulated in clear violation of existing regulations.
NAFDAC further disclosed that laboratory analysis conducted on some of the seized products confirmed significant quality failures, raising grave public health concerns.
Critically low levels of Active Pharmaceutical Ingredients (API) were detected in Linmoxyn (Amoxicillin) suspension and Linmoxyn (Amoxicillin 500mg capsules).
Specifically, Linmoxyn suspension failed quality tests, recording API contents of 13.9 per cent and 18.4 per cent, far below acceptable limits. Similarly, Linmoxyn capsules recorded an API content of just 48.3 per cent, confirming the product to be grossly substandard.
The agency warned that medicines with low API content pose serious risks, including treatment failure, the development of antimicrobial resistance, and other potential safety concerns to consumers.
It also noted that other products bearing various NAFDAC Registration Numbers (NRNs) were discovered at the Europharm Laboratories premises during the investigation, raising questions about falsification and regulatory breaches.
Products Listed for Mop-Up and Enforcement Measures
Among the products listed for mop-up are Linocloxin (Ampicillin 125mg and Cloxacillin 125mg) powder for oral suspension 100ml, Linromycine (Erythromycin) powder for suspension 100ml, Linocillin (Ampicillin) powder for oral suspension 50ml, and Linmoxyn (Amoxicillin 125mg) suspension 60ml.
Other affected products include Eurogyl (Metronidazole suspension) 50ml, Naflin (Cough Expectorant) 100ml, Natacid (Magnesium Trisilicate suspension) 100ml, Navit-B Syrup (Vitamin B Complex) 100ml, and Fountain B-12 (Blood Tonic) in 100ml and 200ml bottles.
Also listed are Vitamin-C Syrup 100ml, Eurogyl (Metronidazole) tablets in blister packs of 10×10 tablets and packs of 1,000 tablets, Euramol (Paracetamol) tablets in packs of 1,000, Euramox (Mebendazole 100mg) tablets, Linotrim (Cotrimoxazole suspension) 50ml, and Linoquine (Chloroquine Phosphate syrup 80mg/5ml) 60ml.
NAFDAC said it had directed all its zonal directors and state coordinators to intensify surveillance and ensure the immediate mop-up of the affected products within their respective jurisdictions.
The agency urged distributors, retailers, healthcare professionals, and caregivers to remain vigilant across the supply chain to prevent the distribution, sale, and use of substandard medicines.
It also advised healthcare professionals and members of the public to promptly report any suspected sale or circulation of substandard or falsified medicines and medical devices to the nearest NAFDAC office.
The agency stressed that its enforcement action is part of a broader effort to safeguard public health, restore confidence in regulated medicines, and dismantle networks of falsified and substandard drug circulation across Nigeria.
Rate, Like 👍, Comment 💬, Share this article, Follow us on our social media handles, and Submit your own story to get featured and earn rewards!
WhatsApp Channel
Telegram Channel
